| Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 1085 | 2014 |
| Oxaliplatin: a review in the era of molecularly targeted therapy T Alcindor, N Beauger Current oncology 18 (1), 18-25, 2011 | 564 | 2011 |
| 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ... The Lancet Oncology 20 (10), e566-e581, 2019 | 489 | 2019 |
| Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 391 | 2019 |
| 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 D Farge, C Frere, JM Connors, AA Khorana, A Kakkar, C Ay, A Muñoz, ... The Lancet Oncology 23 (7), e334-e347, 2022 | 290 | 2022 |
| Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre … WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ... The lancet oncology 18 (8), 1089-1103, 2017 | 283 | 2017 |
| Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients … GD Demetri, SP Chawla, I Ray-Coquard, A Le Cesne, AP Staddon, ... Journal of Clinical Oncology 31 (19), 2485-2492, 2013 | 282 | 2013 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 279 | 2019 |
| Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial N Pavlakis, KM Sjoquist, AJ Martin, E Tsobanis, S Yip, YK Kang, YJ Bang, ... Journal of Clinical Oncology 34 (23), 2728-2735, 2016 | 243 | 2016 |
| PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma CW Ryan, O Merimsky, M Agulnik, JY Blay, SM Schuetze, BA Van Tine, ... Journal of Clinical Oncology 34 (32), 3898-3905, 2016 | 193 | 2016 |
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ... The lancet oncology 21 (8), 1066-1076, 2020 | 187 | 2020 |
| Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations B Melosky, R Burkes, D Rayson, T Alcindor, N Shear, M Lacouture Current oncology 16 (1), 16, 2009 | 176 | 2009 |
| Nirogacestat, a γ-secretase inhibitor for desmoid tumors M Gounder, R Ratan, T Alcindor, P Schöffski, WT Van Der Graaf, BA Wilky, ... New England Journal of Medicine 388 (10), 898-912, 2023 | 169 | 2023 |
| Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine GD Demetri, P Schöffski, G Grignani, JY Blay, RG Maki, BA Van Tine, ... Journal of Clinical Oncology 35 (30), 3433-3439, 2017 | 162 | 2017 |
| European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of … I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... Lancet Oncol 15 (4), 415-423, 2014 | 152 | 2014 |
| Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease T Alcindor, G Gorgun, KB Miller, TF Roberts, K Sprague, DP Schenkein, ... Blood, The Journal of the American Society of Hematology 98 (5), 1622-1625, 2001 | 133 | 2001 |
| Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial LE Ferri, S Ades, T Alcindor, M Chasen, V Marcus, M Hickeson, G Artho, ... Annals of oncology 23 (6), 1512-1517, 2012 | 130 | 2012 |
| Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline MA Shah, EB Kennedy, AE Alarcon-Rozas, T Alcindor, AN Bartley, ... Journal of Clinical Oncology 41 (7), 1470-1491, 2023 | 123 | 2023 |
| Sideroblastic anaemias T Alcindor, KR Bridges British Journal of Haematology 116 (4), 733-743, 2002 | 109 | 2002 |
| A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer V Pacheco-Barcia, RM Solís, T France, J Asselah, O Donnay, ... Pancreatology 20 (2), 254-264, 2020 | 62 | 2020 |
